This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Retinitis pigmentosa (RP) is a group of rare genetic diseases that affect the light-sensitive part of the eye, called the retina. “Atypical RP” refers to RP that lacks the characteristic features of ...

Chitra Kannabiran, PhD, Kallam Anji Reddy Molecular Genetics Laboratory, Hyderabad Eye Research Foundation, Champalimaud Translational Centre, LV Prasad Eye Institute, Hyderabad 500 034, India ...

Retinal degeneration in the disease retinitis pigmentosa is caused by a family of hereditary mutations that slowly lead to blindness over years or decades. A mouse model of one of these forms of ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds, described in a study published January 14 th in the open-access ...

Before you submit an error, please consult our Video Help page. Carolina Impact is available to stream on pbs.org and the free PBS App, available on iPhone, Apple TV, Android TV, Android smartphones, ...

Retinitis is an eye condition where the tissue at the back of the eyeball becomes inflamed. It can lead to reduced vision and vision loss. The tissue at the back of the eye is known as the retina. It ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The investigational cell therapy is designed to replace ...

STOCKHOLM — Trial results are demonstrating the safety and effectiveness of a novel gene modifier therapy for treating retinitis pigmentosa associated with NR2E3 and RHO mutations. Researchers ...

One of those genes encodes the enzyme DHDDS, part of the pathway that glycosylates proteins in higher cells. Retinitis pigmentosa from DHDDS mutations is called RP59. This is a recessive genetic ...

According to Aldeyra Therapeutics, a phase 2/3 trial of ADX-2191 in patients with retinitis pigmentosa is expected to begin in 2025. The Food and Drug Administration (FDA) has granted Fast Track ...